Liquidation: Vor Biopharma Inc.

Form Type: 8-K

Filing Date: 2025-05-08

Corporate Action: Liquidation

Type: New

Accession Number: 000119312525115554

Filing Summary: On May 5, 2025, Vor Biopharma Inc.'s board of directors approved the wind down of the company's clinical and manufacturing operations as part of a strategy to maximize shareholder value. This decision involves a workforce reduction of approximately 147 full-time employees, representing about 95% of the current staff, with total costs related to this wind down estimated at roughly $19.3 million. Associated costs include $3.5 million in termination-related costs for clinical trials, $0.5 million for exit costs from the manufacturing facility, a $4.4 million loss on disposal of fixed assets, and $10.9 million related to the workforce reduction, with most expenses expected in the second quarter of 2025. On May 8, 2025, the company announced the termination of Han Choi as Chief Financial Officer and Tirtha Chakraborty, PhD, as Chief Scientific Officer, effective May 16, 2025. Both executives will receive severance payments and continued health coverage as part of their separation agreements. Additionally, on the same day, the company issued a press release initiating a process to explore strategic alternatives to enhance shareholder value.